Weight Loss in the Elderly: What's Normal and What's Not

P and T

Volumn 28, Issue 11, 2003, Pages 734-739

  Lewko, Michael ^a   Chamseddin, Ayham ^a   Zaky, Maged ^a   Birrer, Richard B ^a  

^a ST JOSEPH S REGIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CYPROHEPTADINE; DRONABINOL; GHRELIN; HUMAN GROWTH HORMONE; MEGESTROL ACETATE; METOCLOPRAMIDE; MIRTAZAPINE; OXANDROLONE; TESTOSTERONE;

ADRENAL INSUFFICIENCY; AGED; ANALGESIA; ANAMNESIS; ANOREXIA; ANTIEMETIC ACTIVITY; ARTHRALGIA; CARPAL TUNNEL SYNDROME; CONFUSION; CONSTIPATION; DEEP VEIN THROMBOSIS; DELIRIUM; DEPRESSION; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DROWSINESS; DYSTONIA; EDEMA; GYNECOMASTIA; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOGONADISM; MORBIDITY; MORTALITY; MYALGIA; PALLIATIVE THERAPY; PARKINSONISM; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; REVIEW; SOMNOLENCE; TERMINAL CARE; VERTIGO; WEIGHT REDUCTION;

EID: 0345133454     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Bouras EP, Lange SM, Scolapio JS. Rational approach to patients with unintentional weight loss. Mayo Clin Proc 2001;76(9):923-929.
2. Smith GP, Gibbs J. The satiating effects of cholecystokinin. Curr Concepts Nutr 1988;16:35-40.
3. Levine AS, Morley JE. Peripherally administered somatostatin reduces feeding by a vagal mediated mechanism. Pharmacol Biochem Behav 1982;16:897-902.
4. Morley JE, Flood JF, Horowitz M, et al. Modulation of food intake by peripherally administered amylin. Am J Physiol 1994;267: R178-R184.
5. Schwartz MW, Woods SC, Porte D Jr, et al. Central nervous system control of food intake. Nature 2000;404(6778):661-671.
6. Sanders CM. The Management of Terminal Illness. New York: Hospital Medicine Publications; 1967.
7. Fabiny AR, Kiel DP. Assessing and treating weight loss in nursing home patients. Clin Geriatr Med 1997;13:737-751.
8. Buckler DA, Kelber ST, Goodwin JS. The use of dietary restriction in malnourished nursing home patients. J Am Geriatric Soc 1994;42:1100-1102.
9. Reife CM. Involuntary weight loss. Med Clin North Am 1995;79:299-313.
10. Morley JE. Anorexia of aging: Physiologic and pathologic. Am J Clin Nutr 1997;66:760-773.
11. Evans WJ, Campbell WW. Sarcopenia and age-related changes in body composition and functional capacity. J Nutr 1993;123(2 Suppl):465-468.
12. Monroe HN. Protein. In: Hartz SC, Russell RM, Rosenberg IH, eds. Nutrition in the Elderly. The Boston Nutritional Status Survey from the USDA Human Research Center on Aging, Tufts University. London: Smith-Gordon and Co., Ltd.; 1992:75-86.
13. Evans WJ. What is sarcopenia? J Gerontol A Biol Sci Med Sci 1995;50(Special No.):5-8.
14. Dionne IJ, Kinaman KA, Poehlman ET. Sacropenia and muscle function during menopause and hormone replacement therapy. J Nutr Health Aging 2000;4(3):156-161.
15. Mauras N, Hayes V, Welch S, et al. Testosterone deficiency in young men: Marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab 1998;83(6):1886-1892.
16. Iranmanesh A, Lizarralde G, Veldhuis JD. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and half-life of endogenous GH in healthy men. J Clin Endocrinol Metab 1991;73(5):1081-1088.
17. Cuneo RC, Judd S, Wallace JD, et al. The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults. J Clin Endocrinol Metab 1998;83(1):107-116.
18. Gazewood JD, Mehr DR. Diagnosis and management of weight loss in the elderly. J Fam Pract 1998;47:19-25.
19. Marton KI, Sox HC, Krupp JR. Involuntary weight loss: Diagnostic and prognostic significance. Ann Intern Med 1981;95:568-574.
20. Markson EW. Functional, social, and psychological disability as causes of loss of weight and independence in older community-living people. Clin Geriatr Med 1997;13(4):639-652.
21. Barrett-Conner E, Edelstein S, Corey-Bloom J, Wiederholt W. Weight loss precedes dementia in community-dwelling older adults. J Nutr Health Aging 1998;2(2):113-114.
22. Carr-Lopez SM, Phillips SK. The role of medications in geriatric failure to thrive. Drugs Aging 1996;9:221-225.
23. Schiffman SS. Taste and smell losses in normal aging and disease. JAMA 1997;278:1357-1362.
24. Brymer C, Winograd CH. Fluoxetine in elderly patients: Is there cause for concern? J Am Geriatr Soc 1992;40:902-905.
25. Guigoz Y, Vellas B, Garry PJ. Assessing the nutritional status of the elderly: The Mini Nutritional Assessment as part of the geriatric evaluation. Nutr Rev 1996;54:S59-S65.
26. Morley JE, Kraenzle D. Causes of weight loss in a community nursing home. J Am Geriatr Soc 1994;42:583-585.
27. Calle EE, Thun MJ, Petrelli JM, Rodriguez C. Body mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999;341:1097-1105.
28. Beck AM, Ovesen L. At which body mass index and degree of weight loss should hospitalized elderly patients be considered at nutritional risk? Clin Nutr 1998;17:195-198.
29. Stevens J, Cai J, Pamuk ER, et al. The effect of age on the association between body mass index and mortality. N Engl J Med 1998;338(1):1-7.
30. Reynolds MW, Fredman L, Langenberg P, Magaziner J. Weight, weight change, mortality in a random sample of older community-dwelling women. J Am Geriatr Soc 1999;47(12):1409-1414.
31. Landi F, Zuccala G, Gambassi G, et al. Body mass index and mortality among older people living in the community. J Am Geriatr Soc 1999;47(9):1072-1076.
32. Morley JE, Silver AJ. Nutritional issues in nursing home care. Ann Intern Med 1995;123:850-859.
33. Fiatarone MA, O'Neill EF, Ryan ND, et al. Exercise training and nutritional supplements for physical frailty in very elderly people. N Engl J Med 1994;330:1769-1775.
34. Lipschitz DA. Approaches to the nutritional support of the older patient. Clin Geriatr Med 1995;11:715-724.
35. Morley JE. Anorexia in older persons: Epidemiology and optimal treatment. Drugs Aging 1996;8:134-155.
36. Wilson MM, Purushothaman R, Morley JE. Effect of liquid dietary supplements on energy intake in the elderly. Am J Clin Nutr 2002; 75(5):944-947.38.
37. Bruera E, Sweeney C. Cachexia and asthenia in cancer patients. Lancet Oncol 2000;1:138-147.
38. Gagnon B, Bruera E. A review of the drug treatment of cachexia associated with cancer. Drugs 1998;55(5):675-688.
39. Bakashi V, Elliot M, Getili A, et al. Testosterone improves rehabilitation outcomes in ill older men. J Am Geriatr Soc 2000;48:550-553.
40. Demling R, DeSanti L. The beneficial effects of the anabolic steroid oxandrolone in the geriatric burn population. Wounds 2003;15:54-58.
41. Yeh SS, DeGuzman B, Kramer T. Reversal of COPD-associated weight loss using the anabolic agent oxandrolone. Chest 2002;122:421-428.
42. Chen HC, Leung SW, Wang CJ, et al. Effect of megestrol acetate and Propulsid on nutritional improvement in patients with head and neck cancers undergoing radiotherapy. Radiother Oncol 1997;43:759.
43. Yeh S, Wu S, Lee T, et al. Improvement in quality of life measures and stimulation of weight gain after treatment with megestrol acetate oral suspension in geriatric cachexia: Results of a double-blind, placebo-controlled study. J Am Geriatr Soc 2000;48:485-492.
44. Castle S, Nguyen C, Joaquin A, et al. Megestrol acetate suspension therapy in the treatment of geriatric/cachexia in nursing home patients. J Am Geriatr Soc 1995;43:835-836.
45. Van Roenn JH, Armstrong D, Katler DP, et al. Magesterol acetate in patients with acquired immunodeficiency syndrome-related cachexia. Ann Intern Med 1994;121:393-399.
46. Karcic E, Philpot C, Morley JE. Treating malnutrition with megestrol acetate: Literature review and review of our experience. J Nutr Health Aging 2002;6:191-200.
47. Yeh SS, Wu SY, Levine DM, et al. The correlation of cytokine levels with body weight after megestrol acetate treatment in geriatric patients. J Gerontol A Biol Sci Med Sci 2001;56:M48-M54.
48. Lambert CP, Sullivan DH, Evan WJ. Effects of testosterone replacement and/or resistance training on interleukin-6, tumor necrosis factor alpha, and leptin in elderly men ingesting megestrol acetate: A randomized control trial. J Gerontol A Biol Sci 2003;58:165-170.
49. Lewko MP, Soliman I. Effectiveness of megestrol acetate (MA) in treating involuntary weight loss in nursing home patients (Abstract). J Am Med Directors Assoc 2000;1:19.
50. Strasser F, Bruera ED. Update on anorexia and cachexia. Hematol Oncol Clin North Am 2002;16(3):589-617.
51. Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety, and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord 1998;51:267-285.
52. Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: A North Central Cancer Treatment Group study. J Clin Oncol 2002;20:567-573.
53. Berry EM, Mechoulam R. Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol Ther 2002;95:185-190.
54. Walsh D, Nelson KA, Mahmoud FA. Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer 2001;11:137-143.
55. Beal JE, Olson R, Lefkowitz I, et al. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 1997;14(1):7-14.
56. Beal JE, Olson R, Lefkowitz I, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995;10:89-97.
57. Volicer L, Stelly M, Morris J, et al. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry 1997;12:913-919.
58. Gonzales-Rasales F, Walh D. Intractable nausea and vomiting due to gastrointestinal mucosal metastases relieved by tetrahydrocannabinol. J Pain Symptom Manage 1997;4:311-314.
59. Glemont-Gnamien S,Atlanti S, et al. The therapeutic use of delta 9 tetrahydrocannabinol in refractory neuropathic pain. Presse Med 2002;31:1840-1845.
60. Wallace JI, Schwartz RS. Involuntary weight loss in elderly outpatients: Recognition, etiologies, and treatment. Clin Geriatr Med 1997;13:717-735.
61. Schambelan M, Mulligan IK, Grunfeld C, et al. Recombinant human growth hormone in patients with HIV-associated wasting: A randomized, placebo-controlled trial. Serostim Study Group. Ann Intern Med 1996;125:873-882.
62. Kardinal CG, Loprinzi CL, Schaid DJ, et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 1990;65:2657-2662.
63. Gorter R. Management of anorexia-cachexia associated with cancer and HIV infection. Oncology [Huntingt] 1991;5:13-17.